| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:18784759 | IVR | 128 mg/kg | 128 mg/kg | Hematopietic carcinoma | Endocrine-mediated cancer;Immunological endocrine-mediated perturbations |
| IVR | 128 mg/kg | 128 mg/kg | Hypertrophy in thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 131 mg/kg | 131 mg/kg | Hypertrophy in thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 131 mg/kg | 131 mg/kg | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 15 mg/kg | 15 mg/kg | Alterations in immune responses | Immunological endocrine-mediated perturbations | |
| IVR | 15 mg/kg | 15 mg/kg | Changes in morphology of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 15 mg/kg | 15 mg/kg | Changes in morphology of pituitary gland | Neurological endocrine-mediated perturbations | |
| IVR | 65 mg/kg | 65 mg/kg | Alterations in immune responses | Immunological endocrine-mediated perturbations | |
| IVR | 65 mg/kg | 65 mg/kg | Changes in morphology of pituitary gland | Neurological endocrine-mediated perturbations | |
| IVR | 65 mg/kg | 65 mg/kg | Hypertrophy in thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 65 mg/kg | 65 mg/kg | Changes in morphology of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 152 mg/kg | 152 mg/kg | Hypertrophy in thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 152 mg/kg | 152 mg/kg | Alterations in immune responses | Immunological endocrine-mediated perturbations | |
| IVR | 152 mg/kg | 152 mg/kg | Changes in morphology of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 152 mg/kg | 152 mg/kg | Changes in morphology of pituitary gland | Neurological endocrine-mediated perturbations | |
| IVR | 13 mg/kg | - | No significant effects observed | - | |
| IVR | 39 mg/kg | - | No significant effects observed | - | |
| IVR | 256 mg/kg | 256 mg/kg | Changes in testicular morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 8 mg/kg | - | No significant effects observed | - | |
| IVR | 256 mg/kg | 256 mg/kg | Hematopietic carcinoma | Endocrine-mediated cancer;Immunological endocrine-mediated perturbations | |
| IVR | 37 mg/kg | - | No significant effects observed | - | |
| IVR | 256 mg/kg | 256 mg/kg | Hypertrophy in thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 58 mg/kg | - | No significant effects observed | - | |
| IVR | 256 mg/kg | 256 mg/kg | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 11 mg/kg | - | No significant effects observed | - | |
| IVR | 7 mg/kg | - | No significant effects observed | - | |
| IVR | 74 mg/kg | - | No significant effects observed | - | |
| IVR | 136 mg/kg | - | No significant effects observed | - | |
| IVR | 64 mg/kg | - | No significant effects observed | - | |
| IVR | 72 mg/kg | - | No significant effects observed | - | |
| IVR | 107 mg/kg | - | No significant effects observed | - | |
| IVR | 52 mg/kg | 52 mg/kg | Hypertrophy in thyroid gland | Metabolic endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.